Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine

Archives of General Psychiatry

Volumn 45, Issue 9, 1988, Pages 789-796

  Kane, John ^a   Honigfeld, Gilbert ^b   Singer, Jack ^b,d   Meltzer, Herbert ^c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

^c STONY BROOK UNIVERSITY   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL;

ADULT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SALIVATION; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA; XEROSTOMIA;

ADULT; CHLORPROMAZINE; CLINICAL TRIALS; CLOZAPINE; COMPARATIVE STUDY; DIBENZAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMAN; MALE; MIDDLE AGE; RANDOM ALLOCATION; SCHIZOPHRENIA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023812652     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1988.01800330013001     Document Type: Article

References (24)

1. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C: Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980;6:70-87.
2. Klein DF, Davis JM: Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Williams & Wilkins, 1969.
3. Kane JM, Lieberman J: Maintenance pharmacotherapy in schizophrenia, in Meltzer HY (ed): Psychopharmacology, the Third Generation of Progress: The Emergence of Molecular Biology and Biological Psychiatry. New York, Raven Press, 1987, pp 1103-1109.
4. Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-483.
5. Peroutka SJ, Snyder SH: Relationship of neuroleptic drug effects at brain dopamine, serotonin, adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 1980;137:1518-1522.
6. Richelson E: Neuroleptics and neurotransmitter receptors. Psychiatr Ann 1980;10:21-26.
7. Richelson E: Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 1984;45:331-336.
8. Hyttel J, Larsen JJ, Christensen AV, Arnt J: Receptor-binding profiles of neuroleptics, in Casey DE (ed): Dyskinesia: Research and Treatment. New York, Springer-Verlag NY Inc, 1985, pp 9-18.
9. Meltzer HY: Clozapine: Clinical advantages and biological mechanisms, in Schulz C, Tamminga C, Chase TN, Christensen AV, Gerlach J (eds): Schizophrenia: A Scientific Focus. New York, Oxford University Press Inc, in press.
10. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS: Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979;136:1550-1555.
11. Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S: Clozapine: Plasma levels and prolactin response. Psychopharmacology 1981;73:184-187.
12. Juul Povlsen U, Noring U, Fog R, Gerlach J: Tolerability and therapeutic effect of clozapine: A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985;71:176-185.
13. Doepp S, Muddeberg C: Extrapyramidale Symptome unter Clozapin. Nervenarzt 1975;46:589-590.
14. Pope HG, Cole JO, Choras PT, Fulwiler CE: Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986;174:493-495.
15. Claghorn J, Honigfeld G, Abuzzahab FS, Wans R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987;7:377-384.
16. Fischer-Cornelssen KA, Ferner UJ: An example of European multicenter trials: Multispectral analysis of clozapine. Psychopharmacol Bull 1976;12:34-39.
17. Griffith RW, Saameli K: Clozapine and agranulocytosis. Lancet 1975;2:657.
18. De la Chapelle A, Kari C, Nurminen M, Hernberg S: Clozapineinduced agranulocytosis. Hum Genet 1977;37:183-194.
19. Lieberman JA, Johns CA, Kane JM, Rai K, Pisciotta AV, Saltz DL, Howard A: Clozapine induced agranulocytosis: Non—cross reactivity with other psychotropic drugs. J Clin Psychiatry 1988;49:271-277.
20. American Psychiatric Association, Committee on Nomenclature and Statistics: Diagnostic and Statistical Manual of Mental Disorders, ed 3. Washington, DC, American Psychiatric Association, 1980.
21. Honigfeld G, Klett G: The nurses' observation scale for inpatient evaluation (NOSIE): A new scale for measuring improvement in chronic schizophrenia. J Clin Psychol 1965;21:65-71.
22. Simpson G, Angus JSW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212(suppl):9-11.
23. Guy W: ECDEU Assessment Manual for Psychopharmacology. US Dept of Health and Human Services publication (ADM) 76-338. Rockville, Md, 1976, pp 534-535.
24. Sackett DL, Gent M: Controversy in counting and attributing events in clinical trials. N Engl J Med 1979;301:1410-1412.